CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ram, T. G.
Right arrow Articles by Ethier, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ram, T. G.
Right arrow Articles by Ethier, S. P.

Cell Growth & Differentiation, Vol 7, Issue 5 551-561, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification

TG Ram and SP Ethier
Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor 48109-0582, USA.

Amplification and overexpression of the c-erbB-2 gene in 21MT-2 and 21MT-1 human breast carcinoma cells results in progressively elevated levels of constitutively tyrosine-phosphorylated p185erbB-2 and is associated with progressive insulin-like growth factor (IGF) and combined IGF/epidermal growth factor (EGF) independence in culture. In addition, the neu differentiation factor/heregulins (HRGs), a family of ligands that activate p185erbB-2 through direct binding to erbB-3 or erbB-4, are potent mitogens for various nonneoplastic mammary epithelial cells and carcinoma cell lines in the absence of both IGF and EGF in culture. We have investigated the ability of ligand induction with HRGs or the constitutive activation of p185erbB-2 in the 21MT breast carcinoma cells to induced the recruitment of phosphatidylinositol 3-kinase (PI3K) by p185erbB-2 and erbB-3. HRG was found to potently induce the recruitment of the M(r) 85,000 regulatory subunit of PI3K by phosphotyrosine proteins in both nonneoplastic H16N-2 mammary epithelial cells (which express normal c-erbB-2 levels) and in the 21MT-2 and 21MT-1 cell lines, which were all isolated from a single patient with intraductal and invasive ductal carcinoma of the breast and express c-erbB-3 but not c-erbB-4 in culture. The activation of PI3K in these cells was also associated with high-level mitogenic responsiveness to HRG, as well as the IGF/EGF-independent proliferation of the 21MT cell lines in culture. The recruitment of PI3K by phosphotyrosine protein during ligand-induced activation, or that seen constitutively in the 21MT tumor cells, did not involve detectable tyrosine phosphorylation of p85. The HRG-induced recruitment of p85 and the constitutive recruitment of p85 in the 21MT cell lines involved direct association with both p185erbB-2 and erbB-3, although greater levels were recruited directly by erbB-3. Wortmannin, a potent inhibitor of PI3K enzymatic activity, also blocked the autonomous proliferation of the 21MT cells, and this effect was reversible in long-term cultures. These data indicate that PI3K may be an especially important mediator of HRG-induced proliferation in mammary epithelial cells and is involved in the autonomous proliferation of growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.


This article has been cited by other articles:


Home page
Cancer Res.Home page
C. Mirschberger, C. B. Schiller, M. Schraml, N. Dimoudis, T. Friess, C. A. Gerdes, U. Reiff, V. Lifke, G. Hoelzlwimmer, I. Kolm, et al.
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Cancer Res., August 15, 2013; 73(16): 5183 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Maegawa, K. Takeuchi, E. Funakoshi, K. Kawasaki, K. Nishio, N. Shimizu, and F. Ito
Growth Stimulation of Non-Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers
Mol. Cancer Res., April 1, 2007; 5(4): 393 - 401.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
N. J. Hellyer, C. B. Mantilla, E. W. Park, W.-Z. Zhan, and G. C. Sieck
Neuregulin-dependent protein synthesis in C2C12 myotubes and rat diaphragm muscle
Am J Physiol Cell Physiol, November 1, 2006; 291(5): C1056 - C1061.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
L A Bazley and W J Gullick
The epidermal growth factor receptor family
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S17 - S27.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Tan, P. Li, K. S. Klos, J. Lu, K.-H. Lan, Y. Nagata, D. Fang, T. Jing, and D. Yu
ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis
Cancer Res., March 1, 2005; 65(5): 1858 - 1867.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. G. Jackson, P. St. Clair, M. X. Sliwkowski, and M. G. Brattain
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
Cancer Res., April 1, 2004; 64(7): 2601 - 2609.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Abe, K. Terada, H. Wakimoto, R. Inoue, E. Tyminski, R. Bookstein, J. P. Basilion, and E. A. Chiocca
PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli
Cancer Res., May 1, 2003; 63(9): 2300 - 2305.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
K. M. Woods Ignatoski, D. L. Livant, S. Markwart, N. K. Grewal, and S. P. Ethier
The Role of Phosphatidylinositol 3'-Kinase and Its Downstream Signals in erbB-2-Mediated Transformation
Mol. Cancer Res., May 1, 2003; 1(7): 551 - 560.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Kumar-Sinha, K. W. Ignatoski, M. E. Lippman, S. P. Ethier, and A. M. Chinnaiyan
Transcriptome Analysis of HER2 Reveals a Molecular Connection to Fatty Acid Synthesis
Cancer Res., January 1, 2003; 63(1): 132 - 139.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
N. J. Hellyer, M.-S. Kim, and J. G. Koland
Heregulin-dependent Activation of Phosphoinositide 3-Kinase and Akt via the ErbB2/ErbB3 Co-receptor
J. Biol. Chem., November 9, 2001; 276(45): 42153 - 42161.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
E. Hintermann, M. Bilban, A. Sharabi, and V. Quaranta
Inhibitory Role of {alpha}6{beta}4-Associated Erbb-2 and Phosphoinositide 3-Kinase in Keratinocyte Haptotactic Migration Dependent on {alpha}3{beta}1 Integrin
J. Cell Biol., April 30, 2001; 153(3): 465 - 478.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. K. Biswas, A. P. Cruz, E. Gansberger, and A. B. Pardee
Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
PNAS, July 18, 2000; 97(15): 8542 - 8547.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falcioni
Cooperative Signaling between {alpha}6{beta}4Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion
J. Biol. Chem., April 7, 2000; 275(14): 10604 - 10610.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
T. G. Ram, M. E. Schelling, and H. L. Hosick
Blocking HER-2/HER-3 Function with a Dominant Negative Form of HER-3 in Cells Stimulated by Heregulin and in Breast Cancer Cells with HER-2 Gene Amplification
Cell Growth Differ., March 1, 2000; 11(3): 173 - 183.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
S. J. Keely and K. E. Barrett
ErbB2 and ErbB3 Receptors Mediate Inhibition of Calcium-dependent Chloride Secretion in Colonic Epithelial Cells
J. Biol. Chem., November 19, 1999; 274(47): 33449 - 33454.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
R. Worthylake, L. K. Opresko, and H. S. Wiley
ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors
J. Biol. Chem., March 26, 1999; 274(13): 8865 - 8874.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Y. W. Bourguignon, H. Zhu, A. Chu, N. Iida, L. Zhang, and M.-C. Hung
Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185HER2, Promotes Human Ovarian Tumor Cell Activation
J. Biol. Chem., October 31, 1997; 272(44): 27913 - 27918.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.